KINETO Lab successfully developed the system to establish, archive and maintain Patient Derived Tumor Xenograft (PDTX) models in immunodeficient mice in order to provide hundreds of options for using the best preclinical models for in vivo drug testing

The urge for development of effective anticancer compounds lead to the massive number of drug candidates produced.

These novel compounds are always going through preclinical testing, involving in vivo antitumor activity testing in traditional xenograft models of rodents, which although offering good pharmacokinetical data, are limited due to cell line based background of cell derived xenografts (CDX), and act dramatically different than clinical tumors, lacking the variety of tumor cells typically present in patients. This often results low success rate in clinical trials after promising preclinical studies.

As reportedly 95% of drug candidates entering clinical trials fail, mostly because lack of effect and safety, and we believe that using better models, such as PDTXs, drastically reduce the unnecessary clinical testing cost during drug development.

Patient-derived tumor xenografts, originated directly from clinical tumors, offer a suitable solutions for drug development.


Properties of the clinical tumor

molecular, morphological and immunohistochemical similarity to clinical disease

Microenvironment and heterogeneity

the structure of the clinical tumor is maintained for several generation of host animals

Metabolism and vascularization

nutritient as well as drug supply is reflected from the patients tumor

Functional activity

the cells in PDTX tumors are alive and functionally active through several generations after serial transplantation


Solutions to drug R&D

the shift from cell line models to PDTXs provides more sophisticated platform in the preclinical drug development

Clinically relevant model

allowing to study drug efficacy in vivo with more relevant data

Reliability of translational research

using the most reliable preclinical models for in vivo drug testing

Predictability of clinical therapeutic response

predicting better the outcomes in the personalized therapy

The figures show that PDTX tumors are preserving the molecular, morphological and immunohistochemical properties of the clinical tumor, while assessment of a PDTX derived cell line — similarly to other traditional cell line xenografts — comes along with a drastic change both tissue structure and molecular marker pattern.


We develop PDTX models resembling tumor heterogeneity and tumor microenvironment for better predictability of clinical therapeutic response


KINETO Lab is collecting clinical samples of various cancer types, establishing and biobanking tumor samples from mice for basic and applied research use.

Read more about PDTX model services

Unique characteristics

Our aim is to collect samples from rare malignancies or metastatic sites as well, in order to provide otherwise hardly accessible disease models and to facilitate metastasis-targeting research.

Here you can find out a list of available PDTX models


10+ clinical oncology
centers source

We work in cooperation with multiple oncological centers in Hungary in order to access and collect broad variety of clinical tumor samples.

precisely validated
and documented

Serial xenografting in immunodeficient mice, and biobanking of different outcome samples allows us to provide well characterized PDTX model collection with complete documentation.

PDTX derived cell line
cultures (PDTX-C)

Also we establish PDTX-C from the models for the investigation of similarities and differences between cell cultures and serial xenografting.


Based on our PDTX database, we are developing our online interface to see all relevant information about our models, including basic clinical data, results of past assays performed on the model, characterization of the model, and its availability.

In vivo tumor experiments, molecular biology samples, or cell lines are equally reachable in order to optimize the tools for every research needs.


Our aim

is to use this PDTX model collection bank in collaboration with other research groups interested in cancer drug R&D, tumor phenotype biomarker research, tumor evolution, tumor genetic background, tumor heterogeneity and therapy resistance experiments.

In case you are interested in our PDTX models, for further details please contact us on

more KINETO Lab

R&D projects

Drug Development



Target Identification